Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 16/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936616 | 0.90 | AOC3 (0.49) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3936170 | 0.90 | AOC3 (0.49) | AOC3 | |
| SCHEMBL3935108 | 0.89 | AOC3 (0.58) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| Hydrochloric Acid SCHEMBL3941479 | 0.88 | AOC3 (0.58) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4874977 | 0.87 | AOC3 (0.76) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3930908 | 0.85 | AOC3 (0.51) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3931455 | 0.85 | AOC3 (0.77) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| Carbamic Acid SCHEMBL3930911 | 0.84 | AOC3 (0.55) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4877656 | 0.84 | AOC3 (0.52) | AOC3 | |
| SCHEMBL5551577 | 0.83 | AOC3 (0.49) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786792-B1 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1786792-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006011631-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | AOC3 386/4885PIK3CD 4021/4885PIK3CA 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.